文献速递肝病

来迪派韦联合索磷布韦(联用或不联用利巴韦林)在经治1型丙型肝炎病毒感染合并肝硬化患者中的安全性与有效性

Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-01-03

多中心前瞻性观察性队列研究(HCV-TARGET)纳入667例经治基因1型丙肝合并肝硬化成人,按区域标准治疗接受来迪派韦联合索磷布韦(联用或不联用利巴韦林)12或24周。符合方案人群610例中579例(93.8%)获得SVR12;多因素分析显示治疗时长与加用利巴韦林均与SVR12无关,而代偿期肝硬化、白蛋白≥3.5 g/dL、总胆红素≤1.2 mg/dL与SVR12相关。

要点

  • 符合方案人群SVR12为93.8%(579/610)。
  • 12周与24周、联用或不联用利巴韦林之间SVR12无显著差异。
  • 代偿期肝硬化、白蛋白≥3.5 g/dL、总胆红素≤1.2 mg/dL与SVR12相关。

核心结论

  • 在HCV-TARGET研究的安全性与有效性分析中,来迪派韦联合索磷布韦(联用或不联用利巴韦林)对经治基因1型丙肝合并代偿期肝硬化患者有效且耐受良好。
  • 12周或24周来迪派韦联合索磷布韦(联用或不联用利巴韦林)治疗的患者SVR12率无显著差异。
  • 失代偿期肝硬化患者似乎可从加用利巴韦林或将来迪派韦联合索磷布韦延长至24周中获益。

研究设计与样本

  • 多中心、前瞻性、观察性队列研究(HCV-TARGET),在美国、加拿大、德国和以色列的39家学术中心与18家社区中心开展。
  • 纳入667例经治成人慢性基因1型HCV感染合并肝硬化患者,于2011年至2016年9月15日期间按区域标准治疗开始来迪派韦联合索磷布韦(联用或不联用利巴韦林)治疗。
  • 符合方案人群(n=610)限于完成12或24周治疗(±2周)且有最终病毒学结局的患者。

主要发现

  • 符合方案分析中579例(93.8%)获得SVR12。
  • 来迪派韦联合索磷布韦12周组50/51例(98%)获得SVR12。
  • 来迪派韦联合索磷布韦24周组384/408例(94.1%)获得SVR12。
  • 来迪派韦联合索磷布韦加利巴韦林12周组68/70例(97.1%)获得SVR12。
  • 来迪派韦联合索磷布韦加利巴韦林24周组57/60例(95%)获得SVR12。

关键数值与推荐

  • 多因素分析显示治疗时长与加用利巴韦林均与SVR12无关。
  • 代偿期肝硬化与失代偿期肝硬化相比,OR为2.41(95%CI 1.16-5.02),与SVR12相关。
  • 白蛋白≥3.5 g/dL,OR为3.15(95%CI 1.46-6.80),与SVR12相关。
  • 总胆红素≤1.2 mg/dL,OR为3.34(95%CI 1.59-7.00),与SVR12相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We aimed to evaluate the safety and effectiveness of 12 or 24 weeks treatment with ledipasvir and sofosbuvir, with or without ribavirin, in treatment-experienced patients with hepatitis C virus (HCV) genotype 1 infection and cirrhosis in routine clinical practice. Patients were followed in a multi-center, prospective, observational cohort study (HCV-TARGET). METHODS: We collected data from 667 treatment-experienced adults with chronic genotype 1 HCV infection who began treatment with ledipasvir and sofosbuvir, with or without ribavirin, from 2011 through September 15, 2016, according to the regional standards of care, at academic (n = 39) and community (n = 18) centers in the United States, Canada, Germany, and Israel. Information was collected from medical records and abstracted into a unique centralized data core. Independent monitors systematically reviewed data entries for completeness and accuracy. Demographic, clinical, adverse event, and virologic data were collected every 12 weeks during treatment and during the follow-up period. The primary efficacy endpoint was sustained virologic response, defined as a level of HCV RNA below the lower limit of quantification or undetectable at a minimum 64 days after the end of treatment (SVR12). The per-protocol population (n = 610) was restricted to patients who completed 12 or 24 weeks of treatment (±2 weeks) and had final virologic outcomes available. RESULTS: The per-protocol analysis revealed that 579 patients (93.8%) achieved an SVR12, including 50/51 patients who received ledipasvir and sofosbuvir for 12 weeks (98%), 384/408 patients who received ledipasvir and sofosbuvir for 24 weeks (94.1%), 68/70 patients who received ledipasvir and sofosbuvir with ribavirin for 12 weeks (97.1%), and 57/60 patients who received ledipasvir and sofosbuvir with ribavirin for 24 weeks (95%). On multivariate analysis, neither treatment duration nor the addition of ribavirin was associated with SVR12. Compensated cirrhosis (odds ratio [OR] compared to decompensated cirrhosis, 2.41; 95% CI, 1.16-5.02), albumin ≥ 3.5 g/dL (OR, 3.15; 95% CI 1.46-6.80), or total bilirubin ≤ 1.2 mg/dL (OR 3.34; 95% CI, 1.59-7.00) were associated with SVR12. CONCLUSIONS: In an analysis of safety and effectiveness data from the HCV-TARGET study, we found treatment with ledipasvir and sofosbuvir, with or without ribavirin, to be effective and well tolerated by treatment-experienced patients with genotype 1 HCV infection and compensated cirrhosis. There were no significant differences in rate of SVR12 among patients treated with ledipasvir and sofosbuvir for 12 or 24 weeks, with or without ribavirin. Patients with decompensated cirrhosis appear to benefit from the addition of ribavirin or extension of ledipasvir and sofosbuvir treatment to 24 weeks. ClinicalTrials.gov no: NCT10474811.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Lim JK, Liapakis AM, Shiffman ML, et al. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clin Gastroenterol Hepatol. 2018. PMID: 29306043. doi:10.1016/j.cgh.2017.12.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。